ClinicalTrials.gg
Not yet recruitingNCT07851688Updated Oct 1, 2026

A Phase I Clinical Study on the Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Characteristics of GLR1075 Injection in Healthy Trial Participants and Cirrhotic Trial Participants With Ascites and Hypoalbuminemia

A Phase 1 interventional study of placebo GLR1075 Vehicle and Human Serum Albumin(HSA) in Hypoalbuminemia in Cirrhotic Ascites, sponsored by Gan & Lee Pharmaceuticals.. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-01.

Sponsored by Gan & Lee Pharmaceuticals. · Phase 1, Interventional, and Treatment

Updated Oct 1, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
106
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This trial is conducted in China. This study plans to include 3 parts,Part A, a single ascending dose (SAD) study in healthy trial participants; Part B, a multiple dose (MD) study in healthy trial participants; and Part C, a multiple ascending dose (MAD) study in cirrhotic trial participants with ascites and hypoproteinemia. All parts are intended to evaluate the safety, tolerability, and pharmacokinetic and pharmacodynamic profiles of GLR1075.

02

Conditions studied

  • Hypoalbuminemia in Cirrhotic Ascites

Browse trials for

Keywords

  • GLR1075 Injection;Cirrhotic Ascites; Hypoalbuminemia
03

In context

Hypoalbuminemia

41 studies on the registry are indexed under Hypoalbuminemia; 9 are open to participants now.

This study's planned enrollment of 106 is above the median of 70 across 25 interventional studies indexed under Hypoalbuminemia.

Browse Hypoalbuminemia studies →

Lead sponsor

Gan & Lee Pharmaceuticals. is the lead sponsor of 30 studies on the registry; 15 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • PART A:

    1. Signed form (ICF) prior to the trial, with a full understanding of the trial content, procedures, and possible adverse reactions, and able to comply with the and restrictions specified in this protocol.
    2. At the time of informed consent, Male or female aged 18-55 years (inclusive)..
    3. At screening, (BMI) ≥18.5 and ≤26.0 kg/m², with body weight ≥50.0 kg for males and ≥45.0 kg for females.
    4. At screening and before randomization and dosing, women of must have a negative human chorionic gonadotropin (hCG) pregnancy test.
    5. From the time of signing the informed consent form until 90 days after administration of the medicinal product, female trial participants of childbearing potential、male trial participants and their partners must agree to use reliable measures, and trial participants must not donate eggs (oocytes, ova) or sperm for assisted reproductive purposes.

PART B:

  1. Signed informed consent form (ICF) prior to the trial, with a full understanding of the trial content, procedures, and possible adverse reactions, and able to comply with the contraindications and restrictions specified in this protocol.
  2. At the time of informed consent, Male or female aged 18-55 years (inclusive)..
  3. At screening, body mass index (BMI) ≥18.5 and ≤26.0 kg/m², with body weight ≥50.0 kg for males and ≥45.0 kg for females.
  4. At screening and before randomization and dosing, women of childbearing potential must have a negative human chorionic gonadotropin (hCG) pregnancy test.
  5. From the time of signing the informed consent form until 90 days after administration of the investigational medicinal product, female trial participants of childbearing potential、male trial participants and their partners must agree to use reliable contraceptive measures, and trial participants must not donate eggs (oocytes, ova) or sperm for assisted reproductive purposes.

PART C:

  1. Signed informed consent form (ICF) prior to the trial, with a full understanding of the trial content, procedures, and possible adverse reactions, and able to comply with the contraindications and restrictions specified in this protocol.
  2. At the time of informed consent, Male or female aged 18-65 years (inclusive).
  3. At screening, body mass index (BMI) ≥18.5 and ≤28.0 kg/m².
  4. Diagnosed with cirrhotic ascites based on clinical, laboratory, or imaging findings in accordance with the 《Guidelines for the Diagnosis and Treatment of Cirrhotic Ascites (2023)》 issued by the Chinese Society of Hepatology, and abdominal ultrasound at screening confirms grade 1-2 ascites.
  5. Serum albumin ≤30 g/L at screening.
  6. At screening and before randomization/dosing, women of childbearing potential must have a negative human chorionic gonadotropin (hCG) pregnancy test.
  7. From the time of signing the informed consent form until 90 days after the last administration of the investigational medicinal product, female trial participants of childbearing potential and male trial participants and their partners must agree to use reliable contraceptive measures (see Appendix 1), and trial participants must not donate eggs (oocytes, ova) or sperm for assisted reproductive purposes.

Exclusion criteria

Exclusion Criteria:

  • PATR A:

    1. Individuals with an allergic constitution, or a history of allergic diseases such as bronchial asthma, urticaria, or eczema, or known allergy, , or intolerance to the medicinal product or similar products or their , any human plasma-derived human albumin component.
    2. Individuals who are pregnant or breastfeeding at screening, or who plan to become pregnant during the trial.
    3. At screening or before randomization,individuals with abnormalities, as judged by the investigator, in physical examination, vital signs, laboratory tests (complete blood count, urinalysis, blood chemistry, coagulation function), posteroanterior chest X-ray or chest CT, abdominal and urinary system ultrasound, 12-lead , or other auxiliary examinations ;
    4. Individuals with diseases of the nervous system, endocrine system, cardiovascular system, respiratory system, hematologic system, immune system, psychiatric system, digestive system, abnormal liver function, abnormal renal function ( \<90 mL/min/1.73 m²), musculoskeletal system, or any other disease or physiological condition that could significantly alter the absorption, metabolism, or elimination of the drug, as well as individuals with suspected and/or confirmed history of tumors at screening or before randomization.
    5. .Individuals who have participated in another interventional clinical trial and received intervention within 3 months before screening (calculated from the last visit of the above clinical trial) or within 5 half-lives of other investigational medicinal products (whichever is longer); or who plan to participate in another clinical trial before completing all scheduled assessments in this trial.
    6. Individuals with a history of drug abuse or drug addiction or with a positive drug abuse test within 1 year before screening.
    7. Individuals who consume more than 14 units of alcohol per week within 3 months before screening: 1 unit ≈ 360 mL beer, or 45 mL spirits, or 150 mL wine, or who cannot abstain from alcohol during the trial, or with a positive alcohol breath test at screening.
    8. Individuals who smoke more than 5 cigarettes per day within 3 months before screening, or who cannot stop using any tobacco products during the trial, or who consume tobacco products within 48 hours before randomization and dosing.
    9. Individuals who consume excessive tea, coffee, and/or caffeine-rich beverages (more than 8 cups per day, 1 cup ≈ 250 mL) daily within 3 months before screening.
    10. Individuals with a history of needle or blood phobia, or who cannot or are unwilling to undergo repeated venipuncture due to poor tolerance or difficult venous access.
    11. Individuals with any food allergy or special dietary requirements who cannot comply with a unified diet or dietary restrictions.
    12. Any reason that the investigator considers may prevent the trial participant from participating in the study.

      PART B:

    <!-- -->

    1. Individuals with an allergic constitution, or a history of allergic diseases such as bronchial asthma, urticaria, or eczema, or known allergy, hypersensitivity, or intolerance to the investigational medicinal product or similar products or their excipients, any human plasma-derived human albumin component.
    2. Individuals who are pregnant or breastfeeding at screening, or who plan to become pregnant during the trial.
    3. At screening or before randomization,individuals with clinically significant abnormalities, as judged by the investigator, in physical examination, vital signs, laboratory tests (complete blood count, urinalysis, blood chemistry, coagulation function), posteroanterior chest X-ray or chest CT, abdominal and urinary system ultrasound, 12-lead electrocardiogram, or other auxiliary examinations ;
    4. Individuals with diseases of the nervous system, endocrine system, cardiovascular system, respiratory system, hematologic system, immune system, psychiatric system, digestive system, abnormal liver function, abnormal renal function (eGFR \<90 mL/min/1.73 m²), musculoskeletal system, or any other disease or physiological condition that could significantly alter the absorption, metabolism, or elimination of the drug, as well as individuals with suspected and/or confirmed history of tumors at screening or before randomization.
    5. .Individuals who have participated in another interventional clinical trial and received intervention within 3 months before screening (calculated from the last visit of the above clinical trial) or within 5 half-lives of other investigational medicinal products (whichever is longer); or who plan to participate in another clinical trial before completing all scheduled assessments in this trial.
    6. Individuals with a history of drug abuse or drug addiction or with a positive drug abuse test within 1 year before screening.
    7. Individuals who consume more than 14 units of alcohol per week within 3 months before screening: 1 unit ≈ 360 mL beer, or 45 mL spirits, or 150 mL wine, or who cannot abstain from alcohol during the trial, or with a positive alcohol breath test at screening.
    8. Individuals who smoke more than 5 cigarettes per day within 3 months before screening, or who cannot stop using any tobacco products during the trial, or who consume tobacco products within 48 hours before randomization and dosing.
    9. Individuals who consume excessive tea, coffee, and/or caffeine-rich beverages (more than 8 cups per day, 1 cup ≈ 250 mL) daily within 3 months before screening.
    10. Individuals with a history of needle or blood phobia, or who cannot or are unwilling to undergo repeated venipuncture due to poor tolerance or difficult venous access.
    11. Individuals with any food allergy or special dietary requirements who cannot comply with a unified diet or dietary restrictions.
    12. Any reason that the investigator considers may prevent the trial participant from participating in the study.

      PART C:

    <!-- -->

    1. Individuals with an allergic constitution, or a history of allergic diseases such as bronchial asthma, urticaria, or eczema, or known allergy, hypersensitivity, or intolerance to the investigational medicinal product or similar products or their excipients, any human plasma-derived human albumin component, or food allergy.
    2. Individuals who are pregnant or breastfeeding at screening, or who plan to become pregnant during the trial.
    3. Individuals with severe digestive system diseases and complications that the investigator considers unsuitable for participation in this study, including but not limited to grade C at screening or before randomization, grade 3 or 4 hepatic encephalopathy
    4. Individuals with a history of malignant tumors within 5 years before screening (except for adequately treated or resected non- basal cell or squamous cell carcinoma of the skin, or carcinoma in situ of the cervix).
    5. Individuals with severe cardiovascular and cerebrovascular events within 6 months before screening,
    6. Individuals with poorly controlled blood pressure at screening, defined as systolic blood pressure ≥140 mmHg and/or diastolic blood pressure ≥90 mmHg without medication or after stable medication.
    7. Individuals with any of the following abnormal laboratory and/or imaging findings at screening or before randomization:

    1) Complete blood count: \<1.0×10⁹/L, \<30×10⁹/L, white blood cells \<2.0×10⁹/L, \<75 g/L; 2) Blood chemistry: and/or AST >5.0× , total >3.0× ULN; eGFR \<60 mL/min/1.73 m²; 3) Coagulation function: (INR) >1.5; 4) Urinalysis: urine protein ≥1+ and the investigator determines that the participant is unsuitable for the trial; 8. Individuals with a history of drug abuse or drug addiction within 1 year before screening, or with positive alcohol breath test or drug abuse test at screening.

    9. Individuals who consume more than 14 units of alcohol per week within 3 months before screening: 1 unit ≈ 360 mL beer, or 45 mL spirits, or 150 mL wine, or who cannot abstain from alcohol during the trial, or with a positive alcohol breath test at screening.

    10. Individuals who smoke more than 5 cigarettes per day within 3 months before screening, or who cannot stop using any tobacco products during the trial.

    11 Individuals who have participated in another interventional clinical trial and received intervention within 3 months before screening (calculated from the last visit of the above clinical trial) or within 5 half-lives of other investigational medicinal products (whichever is longer); or who plan to participate in another clinical trial before completing all scheduled assessments in this trial.

    12. Individuals with a history of needle or blood phobia, or who cannot or are unwilling to undergo repeated venipuncture due to poor tolerance or difficult venous access.

    13. Any reason that the investigator considers may prevent the trial participant from participating in the study.

Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
106 participants (estimated)

Study arms

  • Placebo comparator
    placebo GLR1075 Vehicle

    GLR1075 Vehicle Injection single dose

    Drug: placebo GLR1075 Vehicle

  • Active comparator
    Human Serum Albumin(HSA)

    GLR1075 Injection multiple doses of intravenous infusion

    Drug: Human Serum Albumin(HSA)

  • Experimental
    GLR1075 Injection

    recombinant human albumin

    Drug: GLR1075 Injection

Interventions

  • Drugplacebo GLR1075 Vehicle

    Single dose of intravenous infusion

  • human albumin injection multiple doses of intravenous infusion

  • DrugGLR1075 Injection

    recombinant human albumin injection single dose or multiple doses of intravenous infusion

06

What researchers measure

Primary outcomes

  1. Number of AEs, number of AE episodes, and incidence rate of AEs

    Time frame: Day1-Day 90 for PART A,Day1-Day 132 for PART B,Day1-Day 104 for PART C

Secondary outcomes

  1. Pharmacokinetics parameters-AUC0-t

    Area under the plasma concentration-time curve from time 0 to last time of quantifiable concentration (AUC0-t)

    Time frame: Day 1-Day 90 for Part A,Day 1-Day132 for Part B

  2. Pharmacokinetics parameters-Cmax

    Maximum Plasma Concentration(Cmax)

    Time frame: Day 1-Day90 for Part A,Day 1-Day132 for Part B

  3. Pharmacokinetics parameters-Tmax

    time to Maximum Plasma Concentration(Tmax)

    Time frame: Day 1-Day 90 for Part A,Day 1-Day132 for Part B

  4. Pharmacodynamic parameters-serum albumin

    Change from baseline in serum albumin level

    Time frame: Day 1-Day 90 for Part A, Day 1-Day132 for Part B, Day 1-Day104 for Part C

  5. Pharmacodynamic parameters-Plasma colloid osmotic pressure

    Change from baseline in Plasma colloid osmotic pressure

    Time frame: Day 1-Day 30 for Part A,Day 1-Day102 for Part B,Day 1-Day104 for Part C

  6. Efficacy end point-serum albumin level

    The proportion of trial participants whose serum albumin level reached 35g/L during the treatment period

    Time frame: Day 1-Day15 for Part C

  7. Immunogenicity-ADA

    Anti-Drug antibody (ADA)

    Time frame: Day 1-Day 90 for Part A,Day 1-Day132 for Part B,Day 1-Day104 for Part C

07

Study locations

1 site
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Oct 2026; primary completion for Dec 2028, 26 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 18, 2026
First posted
Oct 1, 2026
StartEst.
Oct 7, 2026
Primary completionEst.
Dec 30, 2028
CompletionEst.
Dec 31, 2028
Last update
Oct 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 1, 2026
Show all 1 update
  1. Oct 1, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07851688
Responsible party
Sponsor
First posted
Oct 1, 2026
Start date
Oct 7, 2026 (estimated)
Primary completion
Dec 30, 2028 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Oct 1, 2026

Study contacts

Chenchen He
Contact
chenchen.he@ganlee.com
010-56456739
Yunda Zhuge
Contact
zhugeyunda@ganlee.com

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion